How have induced pluripotent stem cells been used to study ALS and Alzheimer disease?

In the field of regenerative medicine, induced pluripotent stem (iPS) cells have become a vital tool for advancing our understanding of neurodegenerative conditions. By reprogramming adult somatic cells—such as skin cells—from patients suffering from amyotrophic lateral sclerosis (ALS) and Alzheimer disease, researchers can create patient-specific cell lines.1

These iPS cells serve as essential human models that allow scientists to explore the underlying mechanisms of these diseases in a controlled laboratory setting. Furthermore, these models are used for the screening of potential new drugs, providing a platform to test therapeutic interventions that may eventually lead to effective treatments. Because these cells are derived from the patients themselves, they offer a unique opportunity to study disease progression in a way that captures the specific genetic background of the individual, bypassing many of the ethical concerns associated with using embryonic stem cells.12